Adults with cystic fibrosis experience higher pain prevalence and severity compared to healthy controls, with significant unmet needs in pain management. New study highlights critical gaps in care.

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Low levels of traffic-related air pollution harms the liver and may raise the risk of metabolic-associated fatty liver disease, a new study in mice suggests.

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

Virtual choir program founder Ashley Ballou-Bonnema shares her selfless story on living with and advocating for a life with the chronic disease.

Risk for HF may be able to be identified via simple and affordable non-invasive liver fibrosis scoring systems among the general US population. Non-invasive liver fibrosis scoring systems that are ...

In December, the FDA approved Vertex’s vanzacaftor, tezacaftor and deutivacaftor (Alyftrek) for the treatment of cystic fibrosis in patients with at least one F508del mutation or another ...

Hepatitis and cirrhosis are both diseases that affect the liver. Since hepatitis and cirrhosis are in many ways on a continuum of disease, the symptoms may be very similar. However, there are a ...

When we hear the word "hepatitis," we tend to associate it with cirrhosis and other disorders affecting the liver. But it's not always the case. As with other persistent, chronic infections, hepatitis ...